160 related articles for article (PubMed ID: 32457305)
1. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
Short NJ; Kantarjian H; Kanagal-Shamanna R; Sasaki K; Ravandi F; Cortes J; Konopleva M; Issa GC; Kornblau SM; Garcia-Manero G; Garris R; Higgins J; Pratt G; Williams LN; Valentine CC; Rivera VM; Pritchard J; Salk JJ; Radich J; Jabbour E
Blood Cancer J; 2020 May; 10(5):61. PubMed ID: 32457305
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
[TBL] [Abstract][Full Text] [Related]
3. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
Sanchez R; Ayala R; Alonso RA; Martínez MP; Ribera J; García O; Sanchez-Pina J; Mercadal S; Montesinos P; Martino R; Barba P; González-Campos J; Barrios M; Lavilla E; Gil C; Bernal T; Escoda L; Abella E; Amigo ML; Moreno MJ; Bravo P; Guàrdia R; Hernández-Rivas JM; García-Guiñón A; Piernas S; Ribera JM; Martínez-López J
Ann Hematol; 2017 Jul; 96(7):1069-1075. PubMed ID: 28451802
[TBL] [Abstract][Full Text] [Related]
8. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.
Cho YU; Kim SO; Chi HS; Park SJ; Jang S; Park CJ; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ; Hong SP
Int J Lab Hematol; 2013 Dec; 35(6):589-600. PubMed ID: 23575252
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
[TBL] [Abstract][Full Text] [Related]
10. RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
[TBL] [Abstract][Full Text] [Related]
11. Droplet digital polymerase chain reaction improves the detection of BCR-ABL1 kinase domain mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Wan L; Ma J; Gong X; Li Q; Wang Y; Wei H; Wang J; Xiao Z; Mi Y
Int J Lab Hematol; 2023 Aug; 45(4):528-532. PubMed ID: 36990968
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
13. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
14. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
Tachibana T; Najima Y; Akahoshi Y; Hirabayashi S; Harada K; Doki N; Uchida N; Fukuda T; Sawa M; Ogata M; Takada S; Tanaka M; Matsuhashi Y; Tanaka J; Onizuka M; Ichinohe T; Atsuta Y; Kako S;
Ann Hematol; 2020 Oct; 99(10):2393-2404. PubMed ID: 32803312
[TBL] [Abstract][Full Text] [Related]
15. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
Andolina JR
Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547
[No Abstract] [Full Text] [Related]
16. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
17. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
[TBL] [Abstract][Full Text] [Related]
18.
Heatley SL; Asari K; Schutz CE; Leclercq TM; McClure BJ; Eadie LN; Hughes TP; Yeung DT; White DL
Leuk Lymphoma; 2021 May; 62(5):1157-1166. PubMed ID: 33390067
[TBL] [Abstract][Full Text] [Related]
19. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
20. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
